Onxeo
Paris
About Onxeo
Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma. Onxeo is headquartered in Paris, France.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $76.2M
- Funding stage: IPO
- Last round: Post-IPO Debt (Apr 2022)
- Ticker: epa:ONXEO
- Website: onxeo.com
- Phone: +330145587600
Industries & Categories
Biopharma, Biotechnology, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/onxeo-187650 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.